Primary Clear Cell Carcinoma of the Ovary ; An Analysis of 9 Cases with Review of the Literature.
- Author:
Jung Eun MOK
;
Ji Yoon JUNG
;
Jun Hee NA
;
Jong Hyeok KIM
;
Bong Hee KIM
;
Joor Rung HUH
;
Yong Man KIM
;
Young Tak KIM
;
Joo Hyun NAM
- Publication Type:Original Article
- Keywords:
Ovarian clear cell carcinoma
- MeSH:
Chungcheongnam-do;
Doxorubicin;
Drug Therapy;
Epirubicin;
Female;
Follow-Up Studies;
Gynecology;
Humans;
Hysterectomy;
Lymph Node Excision;
Obstetrics;
Ovary*;
Parity;
Prognosis;
Retrospective Studies;
Ulsan
- From:Korean Journal of Obstetrics and Gynecology
1998;41(12):3016-3022
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Clear cell carcinoma of the ovary is a clinicopathologic entity with distinct morphologic characteristics and known to be associated with poor prognosis irrespective of stage and prognostic benefits of chemotherapy have not been evidently demonstrated. This represents 2-3.6% of all ovarian malignancies. From October, 1991 to January, 1998, nine patients with primary clear cell carcinoma of the ovary treated in the deptartment of Gynecology and Obstetrics, University of Ulsan, Asan Medical Center were identified, and clinical and histologic review(including architectural pattern, mitotic activity, nuclear grading) was performed retrospectively. The age of the patients ranged from 30 to 67 year(mean+S.D.; 46.0+11.8) and the mean parity was 1.2 (+1.3). Five(55.6%) of nine patients had elevated level of CA 125. The size of the tumors varied from 3 cm to 20 cm with the mean maximal diameter of 12.1 (+6.3) cm. The FIGO stages of the patients were IC(6 cases, 66.7%), IIC (2 cases, 22.2%) and IV(1 case, 11.1%). All patients except one were treated by total abdominal hysterectomy and bilateral salpingoophorectomy with or without omentectomy and pelvic lymph node dissection. All except two were received postoperative chemotherapy with regimens such as CEC (cyclophosphamide + epirubicin + carboplatin), TC(taxol + carboplatin), CC(cyclophosphamide + carboplatin) or CAP (cyclophosphamide + adriamycin + cisplatin). The mean follow-up duration was 14.6 (+ 8.6) months and 8 patients were free of disease and one patient with stage IV disease died of disease during postoperative chemotherapy(4 months after surgery).
